Gene Therapy Market is Expected to Reach 11.6 billion by 2030
Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA® (AveXis) and ZYNTEGLO™ (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.
The USD 11.6 billion (by 2030) financial opportunity within the Gene Therapy Market has been analyzed across the following segments:
Key therapeutic areas
· Autoimmune disorders
· Cardiovascular diseases
· Genetic disorders
· Hematological disorders
· Metabolic disorders
· Ophthalmic disorders
· Oncological disorders
· Others
Type of vector
· Adeno associated virus
· Adenovirus
· Herpes simplex virus type 1
· Lentivirus
· Plasmid DNA
· Retrovirus
· Vaccinia Virus
Type of therapy
· Ex vivo
· In vivo
Type of gene modification
· Gene augmentation
· Immunotherapy
· Oncolytic therapy
· Others
Route of administration
· Intraarticular
· Intracerebellar
· Intramuscular
· Intradermal
· Intravenous
· Intravitreal
· Intravesical
· Subretinal
· Others
Key geographical regions
· North America
· Europe
· Asia-Pacific
For more information, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html
The Gene Therapy Market (3rd Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:
· Advantagene
· Advaxis
· BioMarin
· bluebird bio
· FKD Therapies
· Freeline Therapeutics
· GenSight Biologics
· Gradalis
· Inovio Pharmaceuticals
· Marsala Biotech
· Orchard Therapeutics
· Pfizer
· Sarepta Therapeutics
· Spark Therapeutics
· Tocagen
· Transgene
· uniQure Biopharma
· VBL Therapeutics
· ViroMed
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Gene Delivery Vectors
5. Regulatory Landscape and Reimbursement Scenario
6. Competitive Landscape
7. Marketed Gene Therapies
8. Key Commercialization Strategies
9. Late Stage (Phase II/III and Above) Gene Therapies
10. Emerging Technologies
11. Promising Therapeutics Areas
12. Patent Analysis
13. Mergers and Acquisitions
14. Funding and Investment Analysis
15. Cost Price Analysis
16. Big Pharma Players: Analysis of Gene Therapy Related Initiatives
17. Market Forecast and Opportunity Analysis
18. Vector Manufacturing
19. Case Study: Gene Therapy Supply Chain
20. Conclusion
21. Interview Transcripts
22. Appendix 1: Tabulated Data
23. Appendix 2: List of Companies and Organizations
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415